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Abstract: The long-term efficacy of the Epidermal Growth Factor Receptor (EGFR)-targeted antibody
cetuximab in advanced colorectal cancer (CRC) patients is limited by the emergence of drug-resistant
(persister) cells. Recent studies in other cancer types have shown that cells surviving initial treatment
with targeted agents are often vulnerable to alterations in cell metabolism including oxidative
stress. Vitamin C (VitC) is an antioxidant agent which can paradoxically trigger oxidative stress
at pharmacological dose. Here we tested the hypothesis that VitC in combination with cetuximab
could restrain the emergence of secondary resistance to EGFR blockade in CRC RAS/BRAF wild-type
models. We found that addition of VitC to cetuximab impairs the emergence of drug persisters, limits
the growth of CRC organoids, and significantly delays acquired resistance in CRC patient-derived
xenografts. Mechanistically, proteomic and metabolic flux analysis shows that cetuximab blunts
carbohydrate metabolism by blocking glucose uptake and glycolysis, beyond promoting slow but
progressive ROS production. In parallel, VitC disrupts iron homeostasis and further increases ROS
levels ultimately leading to ferroptosis. Combination of VitC and cetuximab orchestrates a synthetic
lethal metabolic cell death program triggered by ATP depletion and oxidative stress, which effectively
limits the emergence of acquired resistance to anti-EGFR antibodies. Considering that high-dose
VitC is known to be safe in cancer patients, our findings might have clinical impact on CRC patients
treated with anti-EGFR therapies.
Keywords: colorectal cancer; cetuximab; drug resistance; Vitamin C; glucose metabolism; oxidative
stress; ROS; ferroptosis
Cancers 2020, 12, 685; doi:10.3390/cancers12030685 www.mdpi.com/journal/cancers
Cancers 2020, 12, 685 2 of 22
1. Introduction
In a subset of advanced colorectal cancers (CRCs), treatment of RAS wild-type (wt) tumors with
the anti-EGFR antibodies cetuximab or panitumumab leads to the killing of drug-sensitive cells and
tumor volume reduction [1]. Unfortunately, the effect is transitory and the emergence of drug-resistant
cells almost invariably leads to clinical relapses [2,3]. Several strategies have been considered to
overcome secondary resistance to EGFR blockade, including vertical targeting the EGFR-RAS-MEK
axis with multiple drugs. For example, our laboratory and others found that combinatorial treatment
with EGFR antibodies and MEK inhibitors effectively restricts the emergence of drug resistance in CRC
preclinical models [4]. While trials with these agents are still ongoing in RAS wt patients (NCT03087071,
NCT02399943), previous phase I clinical studies in RAS/BRAF mutant patients indicate that combination
of EGFR-targeted antibodies and MEK inhibitors could be limited by treatment-related toxicity [5,6].
This is likely due to the fact that several organs (such as the skin and the gut) rely on the EGFR-RAS-MEK
signaling pathways in adult life and this limits the therapeutic index of inhibiting multiple nodes of
EGFR signaling [7].
In the present study we considered how to restrict the emergence of secondary resistance to
cetuximab while limiting side effects. We reasoned that to prolong the response to EGFR blockade,
concomitant or sequential therapies should ideally target those cells that survive the initial anti-EGFR
treatment, which are often referred to as ‘persister’. Persister cells are thought to represent the
reservoir from which permanently resistant clones eventually emerge. Persisters are characterized by a
drug-tolerant state and rely on not completely characterized genetic, epigenetic, or metabolic rewiring
for their survival [8,9]. Recent evidence indicates that persister cells show increased vulnerability to
oxidative stress [10–12]. We reasoned that Vitamin C (VitC), a water-soluble organic compound that
acts as a pro-oxidant molecule when administered at pharmacological concentrations (0.1–100 mM),
might be valuable in targeting persisters [13,14]. Furthermore, recent data indicate that VitC kills CRC
cells carrying RAS-oncogenic mutations [15–17]. Relevant for our working hypothesis, mutations
in RAS itself or its effectors are known mechanisms of acquired resistance to anti-EGFR antibody
therapies in colorectal cancers [3]. Prompted by these data, we reasoned that the pharmacological
properties of VitC, coupled with the transiently vulnerable state of cetuximab persister cells, could be
exploited to target clones surviving anti-EGFR treatment, extend the clinical efficacy of cetuximab, and
possibly restrict the emergence of acquired resistance to EGFR blockade. This hypothesis has never
been previously tested and is highly attractive considering that high-dose VitC is known to be safe and
well tolerated by cancer patients [18–22].
2. Results
2.1. Cetuximab-Persister Cells are Vulnerable to Vitamin C-Mediated Oxidative Stress
We selected a number of in vitro and in vivo preclinical CRC RAS/BRAF wt models to mimic the
clinical setting in which EGFR blockade is used and tested our hypotheses by treating them with VitC
and cetuximab alone or in combination.
We initially considered cetuximab-sensitive 2D CRC cells (DiFi and CCK81). Treatment with VitC
or cetuximab as single agents impaired DiFi cell growth at different levels, but in both instances a
population of surviving cells was consistently detected (Figure ??A and Figure S1). On the contrary,
combinatorial treatment abrogated the persistence of resistant cells (Figure ??A and Figure S1). We
then performed a clonogenic assay where we first generated, by chronically treating cells for 2 weeks,
a pool of cetuximab-persister cells (Figure ??B) that we next challenged with either VitC, cetuximab,
or their combination (Figure ??C). Cetuximab-tolerant cells were more sensitive to VitC-induced
oxidative stress compared to their parental counterpart (Figure ??B, right panel). The sequential scheme
revealed that the combinatorial treatment was the most effective strategy in impairing the growth of
cetuximab-persister cells (Figure ??C,D).
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Figure 1. Effects of Vitamin C (VitC) treatment on cetuximab-persister colorectal cancer (CRC) cells. 
(A) DiFi cells were seeded (25,000 cells/well) in 24-well plates for a long-term proliferation assay 
under treatment with VitC (1 mM), cetuximab (50 μg/mL), or their combination. When cells seeded 
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treatment with VitC (1 mM), cetuximab (50 µg/mL), or their combination. When cells seeded in the
control wells reached confluence, all wells were fixed with paraformaldehyde and stained with crystal
violet. Representative images from one of three independent experiments are shown. See also Figure S1
for results in CCK81 CRC cells. (B) Generation of DiFi cetuximab-persister cells (red square) by
treating for 2 weeks with cetuximab (100 µg/mL), 5 million DiFi cells were seeded in 10 cm plastic
plates (left part) and tested for sensitivity to cetuximab and VitC after 2 weeks of cetuximab treatment
(right part). DiFi parental cells treated with control media were used as a control (blue square). (C)
Cetuximab-persister cells were further challenged with the indicated treatment (Cetux: 100 µg/mL;
VitC: 2 mM) for two more weeks and then fixed and stained with crystal violet for colony assessment.
Representative images are shown from one of three independent experiments. (D) Colony area was
calculated by the ImageJ software and numbers were normalized on control media (release) treatment.
Error bars represent SD. Ctrl, control; Cetux, cetuximab; VitC, Vitamin C; Combo, combination of VitC
and cetuximab; release, control media. Statistical significance: *p < 0.05; **p < 0.01; (two-tailed unpaired
Student’s t test).
2.2. Concomitant Treatment with Cetuximab and VitC Impairs CRC Cell Growth and Delays Emergence of
Acquired Resistance in 2D and 3D in Vitro Models
Next, we measured the time required for the cells to regain proliferative capabilities, compared
with the parental counterpart in the absence of the drugs [4]. To this end we treated RAS/BRAF
wt CRC cell models with VitC, cetuximab, or a combination of the two drugs and continuously
monitored cell growth (Figure 2A,B). VitC marginally affected proliferation in the early phase, but
the cells rapidly returned to the initial proliferation rates. Cetuximab-treated cells responded more
prominently to the treatment but developed resistance within a few weeks. Notably, when cells were
concomitantly treated with VitC plus cetuximab (Combo), the resistant population was apparently
eradicated (Figure 2A,B). We monitored the plates for several months and no evidence of resistant
colonies was observed (Figure 2A,B). At the end of the experiment, only cell debris was visible at
bright-field microscopy (Figure 2A,B, lower panels). Comparable results were also observed in other
cetuximab-sensitive CRC cell models treated with combination of VitC and cetuximab (Figure S2).
We extended the analysis to two independent patient-derived RAS/BRAF wt cetuximab-sensitive
CRC organoids (IRCC-10C and CRC0078) and challenged them with the same treatments previously
used in the 2D assays. In this setting, VitC did not affect organoid growth, while cetuximab was
effective in restricting organoid size. Combinatorial treatment led to severe disassembly of organoid
structure, as shown by immunostaining of cytoskeletal elements (Figure 2C,D).
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Figure 2. Combinatorial treatment hijacks the emergence of acquired resistance in preclinical CRC 
models in vitro. (A,B) Top part: Time-To-Progression assay performed in (A) DiFi and (B) CCK81 
CRC cell lines. The effect of the indicated treatments on cell proliferation was assessed over time by 
cell counting. Nonlinear fit with exponential growth curve (Graphpad Prism) was applied to data 
points to show growth kinetics. Biological duplicates are shown for treatments on DiFi cells. Bottom 
part: bright-field microscopy images of DiFi and CCK81 cell lines treated with VitC alone and in 
combination with cetuximab were taken at the end of the experiment. (C) RAS/BRAF wild-type (wt) 
cetuximab-sensitive organoids (IRCC-10C-XO) were treated with VitC, cetuximab, and combinatorial 
treatment. At the end of the treatment schedule, organoids were stained with DAPI (blue) and 
phalloidin (Phall, green) in order to assess their 3D cellular structure. Representative images of 
organoids are shown for each condition (n = 3). Scale bar 100 μm (10 μm, 63×). (D) RAS/BRAF wt 
cetuximab-sensitive organoids obtained from a second independent patient (CRC0078) were treated 
with VitC, cetuximab, and combinatorial treatment and then stained with DAPI (blue) and phalloidin 
(Phall, green) in order to assess their 3D cellular structure. Representative images of organoids are 
shown for each condition (n = 3). Scale bar 50 μm (25 μm, 63×). Abbreviations and drug concentrations: 
Ctrl: control; VitC: Vitamin C (1 mM); Cetux: cetuximab (50 μg/mL); Combo: combination of VitC and 
cetuximab. 
2.3. Addition of VitC to Anti-EGFR Therapy Delays the Emergence of Acquired Resistance in Cetuximab-
Sensitive Patient-Derived Xenograft Models. 
To further assess the potential relevance of the combinatorial therapy, we performed in vivo 
experiments, by treating RAS/BRAF wt CRC patient-derived-xenograft (PDX) models sensitive to 
anti-EGFR antibodies. Tumors were allowed to fully establish and then were challenged with VitC, 
Figure 2. Combinatorial treatment hijacks the emergence of acquired resistance in preclinical CRC
models in vitro. (A,B) Top part: Time-To-Progression assay performed in (A) DiFi and (B) CCK81
CRC cell lines. The effect of the indicated treatments on cell proliferation was assessed over time by
cell counting. Nonlinear fit with exponential growth curve (Graphpad Prism) was applied to data
points to show growth kinetics. Biological duplicates are shown for treatments on DiFi cells. Bottom
part: bright-field microscopy images of DiFi and CCK81 cell lines treated with VitC alone and in
combination with cetuximab were taken at the end of the experiment. (C) RAS/BRAF wild-type (wt)
cetuximab-sensitive organoids (IRCC-10C-XO) were treated with VitC, cetuximab, and combinatorial
treatment. At the end of the treatment schedule, organoids were stained with DAPI (blue) and phalloidin
(Phall, green) in order to assess their 3D cellular structure. Representative images of organoids are
shown for each condition (n = 3). Scale bar 100 µm (10 µm, 63×). (D) RAS/BRAF wt cetuximab-sensitive
organoids obtained from a second independent patient (CRC0078) were treated with VitC, cetuximab,
and combinatorial treatment and then stained with DAPI (blue) and phalloidin (Phall, green) in order
to assess their 3D cellular structure. Representative images of organoids are shown for each condition
(n = 3). Scale bar 50 µm (25 µm, 63×). Abbreviations and drug concentrations: Ctrl: control; VitC:
Vitamin C (1 mM); Cetux: cetuximab (50 µg/mL); Combo: combination of VitC and cetuximab.
2.3. Addition of VitC to Anti-EGFR Therapy Delays the Emergence of Acquired Resistance in
Cetuximab-Sensitive Patient-Derived Xenograft Models
To further assess the potential relevance of the combinatorial therapy, we performed in vivo
experiments, by treating RAS/BRAF wt CRC patient-derived-xenograft (PDX) models sensitive to
anti-EGFR antibodies. Tum rs were allowed to fully establish and n were challenged w th VitC,
cetuxi ab, or their combination (Figure 3A). VitC treatment had modes activity an s ightly delayed
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tumor growth, while cetuximab treatment consistently reduced tumor size (Figure 3A). After few
months of treatment, mice treated with cetuximab alone relapsed. Tumor growth eventually resumed
also in mice that received combinatorial treatment (Combo 1, red curve), although this occurred later
than in animals treated with cetuximab as a monotherapy (Figure 3A).
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Figure 3. i t ri l t t e t l s t e ce f ire resista ce i t i a -sensitive
patient-derived xenografts. (A) Left panel: t i -sensitive ( 0078) as expanded
to create four cohorts. t reac aro 300 3 i volu e ice were rando ized
(black arro ) and treated ith vehicle, itC (4 g/kg, intraperitoneal i jecti ), c t i ( ,
intraperitoneal injection), or their combination (Combo 1, red curv ). A delayed combinatorial treatment
called “Combo 2” (blue arrow) was initiated after 13 weeks o cetuximab treatm nt to interc p tumors
in a drug-tolerant condition. Right panel: scatter plot showing comparison and statistical significance
between mice treated with c tuximab, Combo 1, and Com o 2. (B) A second cetuximab-sensitive
CRC PDX model (CRC0121) was expanded to create four cohorts. When tumors reached around
500 mm3 in volume ice were randomized (black arrow) and treated with vehicle, VitC (4 g/kg,
intraperitoneal injection), cetuximab (10 mg/kg, intraperitoneal injection). A delayed combinatorial
treatment (blue arrow, Combo 2) was initiated after 4 weeks of cetuximab treatment to intercept tumors
in a drug-tolerant condition. Right panel: scatter plot showing comparison and statistical significance
between mice treated with cetuximab and Combo 2. Error bars represent SEM. Statistical significance:
n.s., not significant; *p < 0.05; **p < 0.01; (two-tailed unpaired Student’s t-test).
We speculated that prolonged treatment with VitC ab initio could activate compensatory
mechanisms limiting its efficacy in vivo. We therefore aimed at intercepting EGFR-treated tumors in a
drug-tolerant state. To test this, we initiated concomitant VitC dosing (Combo 2, blue curve) a few
weeks after treatment with cetuximab had started. This approach significantly reduced tumor volume
respect to cetuximab-monotherapy and delayed the emergence of resistance (Figure 3A,B). Remarkably,
combinatorial treatment was effective even when cetuximab was delivered to larger tumors (500 vs.
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300 mm3 in size), in two different PDX models (Figure S3 and Figure 3B). Overall, treatments were
well tolerated. Mice were constantly monitored during the experimental procedures and no additional
signs of stress were detected in any of the treatment arms.
2.4. Cetuximab as A Single Agent and in Combination with VitC Impairs Glucose Metabolism
To elucidate the single contribution of VitC and cetuximab treatment to the phenotypes observed
above, and to identify the mechanisms underlying the effects of these treatments, we performed
proteomic and metabolic analysis in CRC cells treated with either agents alone or their combination.
In a SILAC-based comparative assay, CRC cells were treated at different time points (4 and 24 h)
in the presence of isotope-labelled amino acids. Upon incorporation of the labelled amino acids, equal
amounts of protein extracts from treated (Heavy labelled) and untreated (Light labelled) cells were
combined and subjected to mass spectrometry analysis.
Hierarchical clustering analysis of differentially expressed proteins (p < 0.05 and FDR < 0.05)
revealed modulation of proteins involved in multiple biological pathways.
Cetuximab highly affected protein levels in combo-treated cells, as noted by co-clustering of the
two treatments at 4 and 24 h (Figure 4A). As expected, cetuximab treatment determined downregulation
of the EGFR pathway (Figure 4A, green arrow and Figure S4) and, interestingly, a more marked effect
was observed in combo-treated cells, where a rebound reactivation of pERK was not evident as in
cetuximab-treated cells, suggesting that combinatorial treatment might shut off or delay possible
recovery mechanisms in cells (Figure S4). As it is known that EGFR plays a pivotal role in metabolism
of lung and colorectal cancer [23,24], we investigated how cetuximab could affect metabolism in CRC
cells and if any differential pathway could be activated in combination with VitC. We found that
EGFR blockade modulates proteins involved in glucose, nucleotide, amino acid, lipid, and fatty acid
metabolism (Figure 4A and Table S1). In particular, the central carbon metabolism was impaired
through downregulation of the glucose transporter GLUT-1 (SLC2A1), and consequent inhibition of
glucose uptake (Figure 4B), and of the glycolysis-initiating enzyme Hexokinase-2 (HK-2) (Figure 4A
and Figure S5, Table S1). To functionally address how cetuximab, alone or in combination with VitC,
affects glycolysis in our models, we exploited the Seahorse XF96 Extracellular Flux Analyzer to perform
an ExtraCellular Acidification Rate assay (ECAR). We found that cetuximab, alone or in combination
with VitC, impairs glycolytic function in DiFi cells (Figure 4C). When the same assay was performed in
concomitance with a Cell MITO Stress test, we observed that, contrary to control and VitC-treated cells,
cetuximab and combo-treated cells were unable to switch to glycolytic metabolism upon inhibition
of the electron transport chain (ETC) complex (obtained by a combination of Rotenone/Antimycin A,
complex I, and III inhibitor, respectively) (Figure 4D).
These data further confirm that cetuximab, alone or in combination with VitC, impairs glucose
uptake and metabolism.
Proteomic analysis also suggested a switch from glycolysis to oxidative phosphorylation (OXPHOS)
metabolism in cetuximab and combo-treated cells, as highlighted by downregulation of lactate
dehydrogenase enzyme (LDH-A and LDH-B subunits), upregulation of pyruvate dehydrogenase
subunits (PDHA1 and PDHB), and increased expression of respiratory enzymes associated to the ETC
complex III (Table S1 and Figure S6A,B). Consistently, after 24 h of treatment with cetuximab or combo,
total ATP levels were significantly decreased (Figure S7) and residual ATP was mainly originating
from OXPHOS (Figure 4E).
Collectively, these data show that, at least at early timepoints, cetuximab and combo-treated cells
are equally impaired at a metabolic level and this prompted us to look for other differentially activated
proteins when comparing cetuximab versus combo-treated cells. We found that proteins related to
iron metabolism such as ferritin (FT, orange arrow) and transferrin receptor (TFRC, pink arrow) were
respectively up and downregulated in VitC and combo-treated cells at 24 h, thus confirming the
involvement of VitC in perturbating iron metabolism (Figure 4A) [25].
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These data altogether indicate that in our models EGFR blockade induces inhibition of glycolysis
while in parallel VitC causes perturbation of iron metabolism, suggesting that the biological effects
observed in combo-treated preclinical models might be due to an additive metabolic synthetic lethal
effect exerted by the concomitant use of the two drugs.
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Figure 4. Proteomic and metabolic analysis of CRC cells treated with VitC or cetuximab as single agents
or in combination. (A) Hierarchical clustering (HCL) of the proteins differentially expressed (ANOVA
p-value < 0.05) in two independent batches of DiFi cells (RS and XM) treated for 4 and 24 h with
VitC (1mM), cetuximab (50 µg/mL), or the combination. The heat map shows fold change in protein
abundance compared with untreated cells. Blue arrows indicate SLC2A1 (GLUT1, Glucose-Transporter
1) and HK2 (Hexokinase2) proteins; green arrow indicates EGFR; orange and pink arrows indicate
FT (Ferritin) and TFRC (Transferrin Receptor), respectiv ly. (B) DiFi cells wer treated for 4 and 24 h
with the indicat d drugs and gluc se upt ke as measured. One repre entative f three independent
experiment performed ach with technical triplicates is shown; error bars represent ± SD. (C) DiFi
cells were treated for 24 h with VitC (1 mM), cetuximab (50 µg/mL), or their combination and Seahorse
XF96 Extracellular Flux Analyzer was used to measure ExtraCellular Acidification Rate (ECAR) and
(D) ECAR followed by a Cell MITO Stress Test. Continuous values normalized to micrograms of
proteins are shown. Results are reported as mean ± SD of one representative of three independent
experiments performed with at least three technical replicates each. (E) ATP production was measured
by Seahorse XF Real-Time ATP rate assays after 24 h of treatment with the indicated drugs and
source of ATP (glycolysis or oxidative phosphorylation) is shown as percentage of total ATP. R/A:
Rotenone/Antimycin.
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2.5. Vitamin C Alters Iron Homeostasis and Triggers Ferroptosis in CRC Cells
The observation that cetuximab plus VitC treatment leads to cell death in CRC models, while at
the same time influencing oxidative stress and iron metabolism, reminded us of ferroptosis, a recently
described form of cell death that is iron- and reactive oxygen species (ROS)-dependent [26]. Ferroptosis
involves accumulation of ‘free’ iron, which causes oxidative stress through Fenton catalysis, depletion
of the antioxidant glutathione and accumulation of lipid oxidative damage, leading to cell membrane
denaturation [27,28]. We indeed explored whether VitC is able to sustain these three main hallmarks of
ferroptosis [29].
We found that VitC as a single agent or in combination with cetuximab, triggered an increase of
ROS production, and this effect was blunted by administration of the antioxidant N-Acetyl Cysteine
(NAC) in different CRC cell lines (Figure 5A and Figure S8). Notably, in a time course experiment,
cetuximab led to a less intense but progressively stronger ROS upregulation (Figure 5B), likely due to
increased reliance on OXPHOS metabolism. Importantly, the addition of cetuximab prevented the
rapid decay of ROS production observed after VitC treatment and enabled sustained ROS persistence
in combo-treated cells (Figure 5B). Analogous results were obtained when we mimicked cetuximab
effects by a RNA interference assay. Upon EGFR siRNA-mediated downregulation, we observed
slightly increased levels of ROS at 24 and 48 h, which maintained higher ROS levels in combo-treated
cells with respect to cells treated with the single VitC agent (Figure S9).
The levels of FT, a protein involved in iron storage, rapidly increased upon VitC treatment and
then progressively declined, while remaining consistently elevated in combo-treated cells (Figure 5C).
Increased levels of ROS can promote FT chemical reduction and release of iron in the cytoplasm [30,31].
Increased levels of labile iron pool (LIP) were indeed detected upon treatment with VitC, alone and in
combination with cetuximab and this effect could be rescued by deferoxamine (DFO), an iron-chelating
agent that binds free iron in a stable complex (Figure 5D). In parallel, we assessed levels of glutathione,
a potent antioxidant that works also as a cofactor for enzymes involved in ferroptosis [28], in cells
treated with VitC, cetuximab, and their combination and found that, after 24 h, VitC, alone or in combo,
was able to significantly decrease levels of reduced and total glutathione (Figure 5E), suggesting that
VitC treatment can acutely trigger oxidative stress leading to ferroptosis. In addition, we observed
that lipid peroxidation was increased by the addition of VitC in CRC cells (Figure S10A) and that
addition of ferrostatin-1 (FRS-1), a lipid ROS scavenger that prevents oxidized lipid accumulation and
ferroptosis [32], significantly reduced lipid peroxidation in combo-treated cells (Figure S10B).
To further corroborate this evidence, we tested two independent CRC RAS/BRAF wt organoid
models. Increased levels of propidium iodide (PI) were found in organoids, especially in combo-treated
ones, suggesting augmented levels of membrane damage that was rescued by the addition of FRS-1
(Figure 6A,B).
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were treated for 3 h with VitC, cetuximab, or the combination and labile iron pool (LIP) levels were 
measured by a calcein-AM method. LIP levels are inversely correlated with calcein fluorescence, 
indicating in this experiment that LIP levels are increased in cells treated with VitC or combo. 
Deferoxamine (DFO) (200 μM) rescues the increase in LIP at levels comparable to those of the control. 
(E) DiFi cells (12,000 cells/well) were plated in 96-well white walled plate and incubated overnight for 
their attachment to the plate surface. Cells were then treated for 24 h with VitC (1 mM), cetuximab 
(50 μg/mL), or their combination. The GSH/GSSG levels were assessed through GSH/GSSG-Glo™ 
Assay (Promega™) following manufacturer protocol. Data were normalized with respect to total 
GSH/GSSG in untreated cells. Statistical significance for each treatment was calculated with respect 
to GSH or total GSH/GSSG in untreated cells. Bars are the average of three independent experiments. 
Error bars represent SD. Statistical significance: n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001 
(two-tailed unpaired Student’s t-test). 
i . it - e iated ROS production trig ers ferroptosi in CRC cells. (A) DiFi cells were treat d as
indicated for 4 h and ROS levels were measur d; N-acetyl cysteine (NAC, 10 mM) was used as a control
to rescue ROS production in drug treated c lls. Se also Figure S8 for results in C75 and CCK81 CRC
cells. (B) DiFi were treated as in icated and ROS levels were measured after 24, 48, and 72 h. Results
in (A) and (B) are representative of at least three independent experiments; results are normalized
to relative controls and error bars represent SD. (C) Cells were treated as indicated and total protein
lysates were analyzed for ferritin (FT) expression. Actin was used as a loading control. Right panel:
Western blot quantification analysis was performed by the ImageJ software. (D) Cells were treated
for 3 h with VitC, cetuximab, or the co bination and labile iron pool (LIP) levels were measured by a
calcein-AM method. LIP levels are inversely correlated with calcein fluorescence, indicating in this
experiment that LIP levels are increased in cells treated with VitC or combo. Deferoxamine (DFO)
(200 µM) rescues the increase in LIP at levels comparable to those of the control. (E) DiFi cells (12,000
cells/well) were plated in 96-well white walled plate and incubated overnight for their attachment
to the plate surface. Cells were then treated for 24 h with VitC (1 mM), cetuximab (50 µg/mL), or
their combination. The GSH/GSSG levels were assessed through GSH/GSSG-Glo™ Assay (Promega™)
following manufacturer protocol. Data were normalized with respect to total GSH/GSSG in untreated
cells. Statistical significance for each treatment was calculated with respect to GSH or total GSH/GSSG
in untreated cells. Bars are the average of three independent experiments. Error bars represent SD.
Statistical significance: n.s., not significant; *p < 0.05; **p < 0.01; ***p < 0.001 (two-tailed unpaired
Student’s t-test).
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(FRS-1) treatment. (A,B) IRCC-10 - ( ) 78 (B) organoids were treated with VitC,
cetuximab, and combinatorial treatment for 2 weeks a t e stai e it ECHST (blue) and PI
(red) to assess the levels of membrane damage and cell death. F S-1 (2 µ ) as used to rescue the
effects dependent on lipid peroxide toxicity. Representative i ages of organoids are shown for each
condition (n = 3). Scale bar: 50 µ (IRCC-10C-XO) and 100 µ (CRC0078). Quantification with ImageJ
software is shown in the right panel. Treatments: Ctrl, control media; VitC, 1 mM; Cetux, 50 µg/mL;
Combo, VitC 1 mM plus Cetux 50 µg/mL. Error bars represent SD. Statistical significance: n.s., not
significant; *p < 0.05; (two-tailed unpaired Student’s t-test).
Collectively, the above findings depict a potential model in which on one side anti-EGFR treatment
induces downregulation of glycolysis and reduction of ATP levels, thus making cancer cells more
susceptible to the oxidative stress induced by VitC. In parallel, addition of VitC triggers ferroptosis by
increasing the amount of free iron involved in intracellular redox reactions (LIP), that in turn leads to
increase of FT levels [33] and augments ROS production fueled by continuous VitC administration
and exacerbated by concomitant cetuximab provision (Figure 7). Indeed, combinatorial treatment
of pharmacological VitC with cetuximab exerts an unrecoverable metabolic synthetic lethal effect,
ultimately leading to cancer cell death (Figure 7).
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(FT). Cetuximab binds to EGFR and promotes the EGFR pathway and metabolic downregulation; VitC
enters in CRC cells and triggers, by interacting with LIP, ROS formation, which in turn can chemically
reduce FT and promote iron release. The latter will react with VitC, which is continuously provided to
cells and will foster increased ROS production with consequent membrane damage and cell death.
3. Discussion
Acquired resistance in CRC is a fait accompli [2]. A transient benefit from treatment with
anti-EGFR targeted therapies initially occurs due to bulk killing of drug-sensitive RAS/BRAF wt
cells and consequ nt measur ble tumor volume reduction. The surviving clones (i.e., persister
cells) are characterized by a d ug-tolerant state that could rely on different mechanisms, eithe
genetic or nongenetic (i.e., transcriptional, epigenetic, metabolic) [9]. Prolonged exposure to the drug
pr gressively fuels the emerge ce of a het rogeneous resistant population that leads eventually to
the therapeutic failure. We r aso ed th t targeting the tumor in a drug-tolerance state and xploiting
transient m tabolic vulnerabilities mig t represe t an effective strategy t r dicate persist r cl nes,
thus hampering the development of acquir d resista c to the therapy. VitC is an organic molecule
with proved pro-oxidant ffects when administered t high doses [13]; moreover, it has been shown
that VitC might eradicate KRAS/BRAF mutant clones, which in our previous studi s emerged as major
mechanisms of relapse to anti-EGFR therapy [34].
We therefore reasoned that an impaired m t bolic state, determined by EGFR blockade, together
with oxidative str ss imposed by VitC treatment, could improv the efficac of anti-EGFR antibodies
in CRCs. To our knowledge, this is the first study showing that VitC in combination with cetuximab
restricts the emergence of acquired resistance in RAS/BRAF wt CR . We focused RAS/BRAF wt
models to closely mimic the clinical setting where only C C patients with this type f genetic profile
are allowed t r ceive anti-EGFR treatme t.
At a mechanistic level, we show that cetuximab severely impairs central carbon metabolism
by inhibiting t e glucose transporter and consequently glucose uptak . Interestingly, l rge-scale
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proteomic analysis and metabolic flux assays suggest also a switch to OXPHOS metabolism, which
is consistent with previous work showing how cells attempting to survive in a nutrient-depleted
environment enter a quiescence state [35].
The overall effect of EGFR blockade and VitC treatment is reminiscent of data showing that
fasting regimens promote the anti-Warburg effect and reduce MAPK signaling, thus enhancing the
effect of chemo and targeted therapies [36,37]. In line with this, we observed downregulation of
EGFR downstream signaling in both cetuximab and combo-treated cells. Notably, the previously
observed ERK rebound activation [34] was evident only in cetuximab monotherapy treated cells,
but not in the combinatorial arm. This evidence suggests that while cells treated with VitC or
cetuximab monotherapies might be able to recover through activation of defense or escape mechanisms,
combinatorial treatment exerts a metabolic synthetic lethality effect that completely impinges on
survival of persister cells.
We noted that the expression levels of proteins involved in iron homeostasis were perturbed by
VitC treatment and confirmed that this could trigger massive production of ROS with consequent
GSH depletion and membrane lipid damage. According to this experimental evidence in multiple
patient-derived preclinical models, we suggest for the first time that pharmacological doses of VitC
might trigger ferroptosis and that mobilization of iron pools by VitC could represent a promising
strategy to induce ROS-mediated stress and cell death in CRC cells whose metabolism is impaired by
targeted drug treatment [38].
As a functional readout, combinatorial treatment with cetuximab and VitC hampered the growth
of CRC cells, ultimately preventing the emergence of acquired resistance to anti-EGFR targeted therapy
in vitro. Organoid structure was impaired by combinatorial treatment and results in CRC PDXs
suggest that the combination with VitC is superior to EGFR blockade alone also in vivo. Although we
did not observe extensive tumor regression in mice, the effect was still relevant, considering that it
was achieved by addition of a vitamin known to have little or no side effects in humans [18,20]. We
acknowledge that we did not perform analysis of ferroptosis markers in PDXs, so further investigation
should be accomplished to assess contribution of VitC to ferroptosis in these models, taking also into
account that mice, unlike humans, are able to synthesize their own endogenous vitamin C.
Future preclinical studies are also warranted to test whether VitC addition to chemotherapy
and EGFR-targeted antibodies could potentiate the efficacy and duration of recommended first-line
regimens in CRC.
VitC is a known cofactor for several Fe2+ and α-ketoglutarate-dependent dioxygenases, including
enzymes regulating histone and DNA methylation, such as ten-eleven translocation (TET) DNA
hydroxylases. Indeed, it has been reported that VitC can act as an epigenetic remodeling agent on
cancer cells [39,40], as well as on several non-neoplastic cell types, including immune cells [41,42].
The experimental models used in this work (cells, organoids, human tumors transplanted in
immunocompromised animals) were not suited to assess the potential effect of VitC on modulating
anticancer immune responses [43,44]. The activity might therefore be magnified in the presence of a
fully competent immune system.
In conclusion, our data have the potential to be rapidly translated into clinical trials testing the
effects of VitC in combination with EGFR-targeted monoclonal antibodies in metastatic CRC patients.
Contrary to many drug combinations previously tested to curb the emergence of resistance to targeted
therapies, the innovative treatment proposed here is expected to add no or limited toxicity to an already
approved regimen, although we acknowledge that further clinical investigation for establishment of
optimal dosing and scheduling is needed.
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4. Methods
4.1. Cell Lines and Cell Authentication
DiFi cells were a kind gift from Dr. J. Baselga in November 2004 (Oncology Department of Vall
d’Hebron University Hospital, Barcelona, Spain), and were described for the first time in [45]. DiFi
is a KRAS/BRAF wt CRC cell line established from a familial adenomatous polyposis patient and is
sensitive to anti-EGFR blockade due to EGFR gene amplification.
Regarding the other CRC RAS/BRAF wt cell lines described in this study, CCK81 were obtained
from Health Science Research Resources Bank and C75 were obtained from ECACC and cultured
according to supplier guidelines. IRCC-10A was established as described in the next section.
DiFi and IRCC-10A cell lines were cultured in DMEM/F12 medium; CCK81 cell line was cultured
in MEM medium; C75 cell line was cultured in RPMI1640 medium. Culture media was supplemented
with fetal bovine serum (10%), 2 mM L-glutamine, antibiotics (100 U/mL 1 penicillin and 100 mg/mL 1
streptomycin). Cell lines were grown in a 37 ◦C and 5% CO2 air incubator.
The genetic identity of cell lines was authenticated before performing experiments by PowerPlex®
16 HS System (Promega, Madison, WI, USA), through short tandem repeats (STR) at 16 different loci
(D5S818, D13S317, D7S820, D16S539, D21S11, vWA, TH01, TPOX, CSF1PO, D18S51, D3S1358, D8S1179,
FGA, Penta D, Penta E, and amelogenin). Amplicons from multiplex PCRs were separated by capillary
electrophoresis (3730 DNA Analyzer, Applied Biosystems, Foster City, CA, USA) and analyzed using
GeneMapper v.3.7 software (Life Technologies, Carlsbad, CA, USA). All cell lines were also routinely
tested for mycoplasma contamination with the PCR Mycoplasma Detection Kit (ABM, Richmond, BC,
Canada).
4.2. Tumor Specimen and Patient-Derived Model Establishment
Patient tumor samples were obtained from patients treated by liver metastectomy at Niguarda
Cancer Center (Milano, Italy) and Ospedale Mauriziano Umberto I (Torino, Italy). All patients provided
informed written consent, samples were procured and the study was conducted under the approval of
the local Ethical Committee of the institutions (for Niguarda Cancer Cencer: study 194/2010, n.22 date
24th February 2010, for Candiolo Cancer Center: PROFILING study, 001-IRCC-00IIS-10, 6.0 version,
date 24th April 2015).
The study was conducted according to the provisions of the Declaration of Helsinki.
To generate PDXs (patient-derived xenografts), tumor specimens were subcutaneously implanted
in 7-week-old NOD-SCID mice (Charles River Laboratory, Wilmington, MA, USA). Treatments were
performed as described in the in vivo experiments section. The protocol was reviewed by the local
Animal Welfare Body (OPBA) of the Candiolo Cancer Institute IRCCS (Candiolo, Italy) and authorized
by Italian Ministry of Health (Licence Number 195/2015-PR and 154/2019-PR), according to the Italian
Law on the protection of animals used for scientific purposes (DLgs 26/2014) which enforces the EU
Directive 63/2010.
The two PDX models used in this work were derived from quadruple wt (KRAS, NRAS, BRAF
and PIK3CA) cetuximab-sensitive liver metastasis of CRC patients (CRC0078 and CRC0121).
IRCC-10A is a tumor-derived 2D-growing primary cell line obtained from a metastasis located in
the hepatic right lobe of a KRAS wt CRC patient (IRCC-10).
Briefly, the tumor sample was dissociated into single-cell suspension by mechanical dissociation
using the gentleMACS Dissociator (Miltenyi Biotec, Bergisch Gladbach, Germany) and enzymatic
degradation of the extracellular matrix using the Tumor Dissociation Kit (Miltenyi Biotec, Bergisch
Gladbach, Germany) according to the manufacturer’s instructions. The cell suspension was then
centrifuged three times at 1200 rpm for 5 min and washed with DMEM/F12 medium. Supernatants
were removed and cell pellets were resuspended with DMEM/F12 medium containing 10% FBS. The
cell suspensions were then filtered through a 70-µm cell strainer (Miltenyi Biotec, Bergisch Gladbach,
Germany) and resuspended with culture medium DMEM-F12 containing 2 mmol/L l-glutamine,
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antibiotics (100 U/mL penicillin and 100µg/mL streptomycin), 50µg/mL gentamicin, and 10µmol/L
ROCK inhibitor Y-27632 (Selleck Chemicals Inc., Houston, TX, USA ) and cultured on collagen-coated
dish (Corning, NY, USA) at 37 ◦C in 5% CO2.
IRCC-10C-XO and CRC0078-XO organoids were established from PDX models of liver metastases
of cetuximab-sensitive RAS/BRAF wt CRC patients (named IRCC-10 and CRC0078 respectively). In
particular, IRCC-10C-XO was derived from a liver metastatic nodule located in hepatic segment 2,
different from the one from which the abovementioned cell line was derived (right hepatic lobe).
Briefly, tumor specimens were initially smashed in fragments of 2–4 mm in size and then chopped with
scalpel to further mechanically dissociate in small pieces. After centrifugation, the pellet was washed
and centrifuged three times with PBS. At the end of the washing phase, the pellet was resuspended
in Basement Membrane Extract (BME; Cultrex BME RGF type 2, Trevigen, Gaithersburg, MD, USA)
and 60 µL of organoids-BME suspension was dispensed into the center of each well of a 48-well plate.
Different densities of tumor cells were plated and left to solidify before tumor organoid medium was
added and tumor cells were incubated at 37 ◦C and 5% CO2 air incubator. The composition of Tumor
Organoid medium is as follows: DMEM/F12 + Hepes medium supplemented with antibiotics, 1 ×
Primocin (InvivoGen, San Diego, CA, USA), 1% GlutaMax (Invitrogen, Carlsbad, CA, USA), 1×B27
supplement (Invitrogen, Carlsbad, CA, USA), 1.25 mM N-acetyl-cysteine (Sigma Aldrich, St. Louis,
MO, USA), 10 mM nicotinamide (Sigma Aldrich, (Sigma Aldrich, St. Louis, MO, USA), 50 ng/mL
human EGF (PeproTech), 100 ng/mL R-spondin (R&D, Minneapolis, MN, USA), 100 ng/mL Noggin
(PeproTech, London, UK), 10 nM gastrin (Sigma Aldrich, St. Louis, MO, USA), 500 nM TGFb type I
receptor inhibitor A83-01 (Sigma Aldrich, St. Louis, MO, USA), 10 uM p38 MAPK inhibitor SB202190
(Sigma Aldrich, St. Louis, MO, USA), and 10 nM prostaglandin E2 (Tocris, Bristol, UK). Fresh medium
was replaced every 2–3 days. Outgrowing organoids were passaged every 10–15 days after mechanical
and enzymatic disruption.
The treatments of established organoids were performed in DMEM/F12 medium supplemented
with 2 mM L-glutamine, antibiotics (100 U/mL penicillin and 100 mg/mL streptomycin) at 37 ◦C and
5% CO2.
4.3. Drugs and Reagents
Cetuximab was provided by Merck (Darmstadt, Germany). VitC solution (+)-Sodium
L-ascorbate—SigmaTM was prepared weekly by resuspending the powder in PBS for in vitro
experiments. For animal experiments VitC was prepared weekly by resuspending the powder
in sterile water and storing the solution at 4 ◦C.
4.4. Drug Proliferation Assay
Long-term assay: DiFi cells were seeded (25,000 cells/well) in 24-well plate and treated with VitC
(1 mM), cetuximab (50 µg/mL), or their combination. When cells seeded in the control wells reached
confluence (10 days), all wells were fixed with paraformaldehyde and stained with crystal violet.
Short-term assay after generation of cetuximab-persister cells: DiFi cells previously treated for
2 weeks with cetuximab (100 µg/mL) or control medium were detached, counted, seeded in 96-well
plates (3 × 103 cells/well in technical triplicate), and incubated overnight for attachment. The day
after they were treated with increasing amount of cetuximab or VitC and after 6 days viability was
measured by CellTiter-Glo® Luminescent Cell Viability Assay (Promega, Madison, WI, USA) according
to the manufacturer’s protocol. Luminescence was measured using a plate-reading luminometer
(TECAN Spark 10M, Männedorf, Switzerland); the resulting data were normalized to untreated cells
and nonlinear fit analysis was performed with the Prism Graphpad software v. 8.
4.5. Time-To-Progression (TTP) Assay
For the TTP long-term assay, 10 million DiFi cells were plated in their respective growth media
and treated from the day after with cetuximab (50 µg/mL), VitC (1 mM), or the combination of the two.
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All cells were counted at least once per week. Count as 0 represent time points in which cells were
dead or too few and only medium and drug refreshments were done.
4.6. Western Blotting Analysis
Total cellular proteins were extracted by solubilizing the cells in EB buffer (50 mmol/L Hepes pH
7.4, 150 mmol/L NaCl, 1% Triton X-100, 10% glycerol, 5 mmol/L EDTA, 2 mmol/L EGTA; all reagents
were from Sigma-Aldrich (St. Louis, MO, USA), in the presence of 1 mmol/L sodium orthovanadate,
100 mmol/L sodium fluoride, and a mixture of protease inhibitors. Extracts were clarified by
centrifugation and normalized with the BCA Protein Assay Reagent Kit (Thermo Fisher Scientific,
Waltham, MA, USA). Western blot detection was performed with enhanced chemiluminescence system
(GE Healthcare, Chicago, IL, USA) and peroxidase conjugated secondary antibodies (Amersham, Little
Chalfon, UK). The following primary antibodies were used for Western blotting (all from Cell Signaling
Technology, Danvers, MA, USA, except where indicated): anti-phospho-p44/42 ERK (Thr202/Tyr204;
1:1000); anti-p44/42 ERK (1:1000); anti-phospho EGFR (Tyr1068) (1: 1000); anti-EGFR (EnzoLifeSciences,
Farmingdale, NY, USA) (1:1000); anti-ferritin light chain (Abcam, Cambridge, UK) (1:1000); anti-Actin
(Santa Cruz Biotechnology, Dallas, TX, USA) (1:1000).
4.7. Immunofluorescence
Organoids embedded in BME (Cultrex® Basement Membrane Matrix BME, Trevigen, Gaithersburg,
MD, USA) were grown in 8-well chamber slides, in DMEM/F12 10% FBS and treated with the indicated
treatments. Drug was refreshed every 4 days. After 14–21 days, organoids were fixed in 4%
paraformaldehyde for 30 min at room temperature (RT) and permeabilized with 0.5% Triton-X100
in PBS for 30 min RT. Nuclei were stained with DAPI. F-actin was stained with Alexa Fluor® 488 or
Alexa Fluor® 647 Phalloidin (50 µg/mL). Slides were then mounted using the fluorescence mounting
medium (Dako, Glostrup, Denmark) and analyzed using a confocal laser-scanning microscope (TCS
SPE II; Leica, Wetzlar, Germany).
We took advantage also of live/dead staining to assess cell death in organoids by fluorescence
microscopy. Matrigel was disrupted mechanically with a pipette tip and organoids were transferred to
an Eppendorf tube. Organoids were stained in DMEM/F12 medium with 100µg/mL Hoechst 33342
(Sigma Aldrich, St. Louis, MO, USA) and 100µg/mL PI (Sigma Aldrich, St. Louis, MO, USA). After
30 min of incubation in the dark, organoids viability was observed by fluorescent microscopy (Axio
Vert.A1, Zeiss, Oberkochen, Germany).
4.8. In Vivo Experiments
The PDX models used in this study were derived from patients (CRC0078 and CRC0121) carrying
a quadruple wild-type (KRAS, NRAS, BRAF, and PIK3CA) colorectal tumor. Established tumors
(average volume 300 or 500 mm3, as indicated) were treated with the following regimens, either
single-agent or in combination: VitC (Sigma, 4 g/kg, intraperitoneal, daily-5 days per week), cetuximab
(Merck, 10 mg/kg, intraperitoneal, twice weekly). Tumor size was evaluated every week by caliper
measurements, and the approximate volume of the mass was calculated using the formula 4/3 pi (d/2)2
D/2, where d is the minor tumor axis and D is the major tumor axis. Mice were kept under the constant
supervision of veterinary personnel and animal procedures were approved by the Ethical Commission
of the Candiolo Cancer Institute and by the Italian Ministry of Health (Licence Number 195/2015-PR
and 154/2019-PR).
4.9. SILAC (Stable Isotope Labeling by Amino acids in Cell culture) Analysis
For SILAC analysis, two independent batches of DiFi cells (RS and XM Difi cells) were grown in
reconstituted DMEM/F12 medium containing either “light” [12C6, 14N4] arginine (referred to as Arg0)
and [12C6, 14N2] lysine (referred to as Lys0) or “heavy” [13C6, 15N4] arginine (referred to as Arg10) and
[13C6, 15N2] lysine (referred to as Lys8) stable isotope labelled amino acids (Thermo Fisher Scientific,
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Waltham, MA, USA). After at least six passages to allow the incorporation of the isotopes into the
cellular proteome, both RS and XM DiFi cell populations, labelled with heavy isotopes, were treated
with VitC (1mM), cetuximab (50 µg/mL), and their combination for 4 and 24 h. The nontreated control,
labelled with light isotopes, was cultured in parallel with the treated cells. After verification of the
incorporation efficiency, DiFi cells pellet was solubilized in 8 M urea, 0.1 M Tris/HCl pH 8.5 (UA buffer)
and equal amounts of protein extracts from treated and untreated labelled cells were combined 1:1,
then subjected to mass spectrometry analysis.
4.10. Mass Spectrometry Analysis
About 50 µg of proteins for each sample were reduced by TCEP, alkylated by chloroacetamide, and
digested overnight by Lys-C and trypsin [46]. Derived peptides were desalted on StageTip C18 [47].
Samples were analyzed in duplicate on a LC–ESI–MS-MS quadruple Orbitrap QExactive-HF mass
spectrometer (Thermo Fisher Scientific, Waltham, MA, USA). Peptides separation was achieved on a
linear gradient from 95% solvent A (2% ACN, 0.1% formic acid) to 50% solvent B (80% acetonitrile,
0.1% formic acid) over 120 min, and from 50% to 100% solvent B in 2 min at a constant flow rate of
0.25 µL/min on UHPLC Easy-nLC 1000 (Thermo Fischer Scientific, Waltham, MA, USA) connected
to a 23 cm fused-silica emitter of 75 µm inner diameter (New Objective, Inc. Woburn, MA, USA),
packed in-house with ReproSil-Pur C18-AQ 1.9 µm beads (Dr Maisch Gmbh, Ammerbuch, Germany)
using a high-pressure bomb loader (Proxeon, Odense, Denmark). MS data were acquired using a
data-dependent top 15 method for HCD fragmentation. Survey full scan MS spectra (300–1650 Th)
were acquired in the Orbitrap with 60,000 resolution, AGC target 3e6, IT 20 ms. For HCD spectra,
resolution was set to 15,000 at m/z 200, AGC target 1e5, IT 80 ms. For identification and quantitation,
Raw MS files were processed with MaxQuant software (1.5.2.8, https://www.maxquant.org) making
use of the Andromeda search engine [48]. MS/MS peak lists were searched against the database
uniprot_cp_human_2015_03, in which multiplicity was set as 2, trypsin specificity was used with up to
two missed cleavages allowed. Cysteine carbamidomethyl was used as fixed modification, methionine
oxidation and protein N-terminal acetylation as variable modifications. The peptides and protein false
discovery rates (FDR) were set to 0.01; the minimal length required for a peptide was six amino acids;
a minimum of two peptides, of which one unique was required for protein identification.
Normalized H/L ratios of proteins identified were analyzed via Perseus (version 1.5.6.0, https:
//maxquant.net/perseus). t-test and ANOVA statistical analysis was performed applying FDR < 0.05 or
p-value < 0.05 as reported.
4.11. Glucose Uptake Assay
Twelve thousand DiFi cells were plated in 80 uL of DMEM/F12 media on day 1. On day 2 cells
were treated for 4 and 24 h with the indicated drugs and glucose uptake was measured with the Glucose
Uptake-Glo Assay (Promega, Madison, WI, USA) after incubation for 10 min in glucose-deprived
medium supplemented with 1 mM 2-Deoxy-D-Glucose (2DG). Glucose-uptake values were normalized
on cell viability; experiments were repeated three times with technical triplicates.
4.12. Seahorse Metabolic Experiments
Real-time measurements of extracellular acidification rate (ECAR) were made using an XFe96
Extracellular Flux Analyzer (Agilent Technologies, Santa Clara, CA). ECAR was measured on 17,000
cells, pretreated with the indicated drugs, using Glycolysis Stress Test kit, in basal conditions and in
response to glucose (10 mM), oligomycin (1 µM), and 2-Deoxy-D-glucose (2-DG, 50 mM). The MITO
stress experiment was performed using MITO Stress Test Kit following the manufacturer’s protocol and
standard concentrations of oligomycin (1µM), carbonylcyanide-4- (trifluoromethoxy)-phenylhydrazone
(FCCP, 1 µM), and Rotenone/Antimycin A (0.5 µM). All reagents were from Agilent (Santa Clara, CA,
USA).
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To evaluate the rate of adenosine triphosphate (ATP) production in living cells, distinguishing
between the fractions of ATP that are produced from OXPHOS and glycolysis, Agilent Seahorse XF
Real-Time ATP rate assay was used following the manufacturer’s instructions.
Results were analyzed in WAVE software (version 2.6, Agilent), normalized on cellular protein
concentration (OD), and processed through the XF Cell MITO Stress Test Report, Glycolysis Stress Test
Generator and ATP rate assay generator. Each experiment was repeated at least three independent
times with technical triplicates.
4.13. H2O2 Detection Assay
DiFi cells were seeded in a 96-well white walled plate (12 × 103 cells/well) in 60 µL of medium
per well and incubated overnight for their attachment to the plate surface. ROS-Glo™ H2O2 Assay
(Promega™) was exploited to assess H2O2 levels. Then, 20 µL of a medium 5× drug-containing solution
and 20 µL of H2O2 substrate solution (the latter only in the last 4 h of the treatment) were added to
each well, reaching a final volume of 100 µL. The cells were placed in a 37 ◦C and 5% CO2 air incubator
for 4, 24, 48, and 72 h of treatment. At the end of the treatment, 100 µL of ROS-Glo™Detection Solution
was added to each well. The relative luminescence was measured using a plate-reading luminometer
(TECAN Spark 10M instrument) after 20 min of incubation at room temperature. The resulting data
were normalized to untreated cells.
N-acetyl-L-cysteine (NAC, Sigma Aldrich, St. Louis, MI, USA) was used at the concentration of
10 mM to perform the rescue experiments.
4.14. siRNA Screening
The siRNA targeting reagents were purchased from Dharmacon (Lafayette, CO, USA), as a
SMARTpool of four distinct siRNA species targeting different sequences of the target transcript. Cell
lines were grown and transfected with SMARTpool siRNAs (20 nmol/L) using RNAiMAX (Invitrogen
Carlsbad, CA, USA) transfection reagents following manufacturer’s instructions in a 96-well white
plate for ROS assay and in 6-well plates for Western blot analysis after 48 and 72 h post-transfection.
AllStars (Qiagen, Hilden, Germany) nontargeting siRNA was used as negative control. For ROS assay,
cells were treated the day after transfection.
4.15. Labile Iron Pool (LIP) Level Analysis
DiFi cells were plated in 96-well microplates for fluorescence assays and incubated overnight for
their attachment to the plate surface. Calcein AM solution (C1359, Sigma Aldrich, St. Louis, MI, USA)
was added to each well following manufacturer’s instructions and fluorescent levels were measured
by TECAN Spark 10M instrument. LIP levels are inversely correlated with calcein fluorescence.
Deferoxamine mesylate (DFO, Sigma Aldrich, St. Louis, MI, USA) was supplemented at 200 µM
to cells to perform the rescue experiment.
4.16. Membrane Lipid Peroxidation Detection Assay
Twenty million DiFi cells were plated in 15 cm Petri dishes (two dishes per treatment) and then
treated for 24 h with VitC, cetuximab, or their combination. Lipid peroxidation was assessed using the
OxiSelect™ TBARS Assay Kit (Cell Biolabs, San Diego, CA, USA). Cells were counted and an equal
amount for each sample was resuspended in PBS containing 1× BHT. Cell suspensions were then
sonicated. Whole homogenate was then processed following manufacturer protocol. Ferrostatin-1
(FRS-1, Sigma Aldrich, St. Louis, MI, USA) was used at the final concentration of 2 µM to perform the
rescue experiment.
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4.17. Statistical Analysis
Results were expressed as means ± standard error of the mean (SEM) or standard deviation (SD)
as indicated in the legend. Statistical significance was evaluated by unpaired two-tailed Student’s t-test,
using GraphPad Prism® 8.00 (GraphPad Software, Inc., La Jolla, CA, USA). p < 0.05 was considered
statistically significant.
5. Conclusions
EGFR-targeted therapies have shown limited efficacy in mCRC patients due to the emergence of
acquired resistance. The identification of ‘non-toxic’ therapeutic combinations capable of restraining
secondary resistance represents therefore an urgent clinical need. Here we provide the first evidence
that concomitant cetuximab-induced metabolic rewiring of CRC cells and vitamin C-mediated oxidative
stress might restrict the emergence of secondary resistance to EGFR blockade. These findings could
pave the way to future clinical experimentations involving RAS/BRAF wt mCRC patients treated with
anti-EGFR antibodies.
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